Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy

Inclusion Criteria: * Predominant clinical diagnosis of SUI * Stress incontinence ≥ grade I for at least 6 months * Patient has at least once been treated with, and failed prior conservative treatments * Patient had no improvement of SUI symptoms for at least 6 months before enrollment * Patients with a certain amount of leaks or /and a predefined pad weight at screening * Candidate for a surgical treatment * Negative blood test: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C, Anti-HCV-Ab and Syphilis * Negative laboratory or blood test, and medical examination to eliminate risk of sexually transmitted diseases (STD) per investigators' discretion * Competent to comprehend, sign, and date informed consent form before any study-specific procedure is performed * Able to communicate well with the Investigator, and to understand and comply with the requirements of the study including answering the required questionnaires Exclusion Criteria: * History of anti-incontinence surgery or prolapse surgery. * Prolapse * Diagnosed Hypermobile Urethra * Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract: * Clinically significant cystocele or rectocele * Ureteric bladder, urethral or rectal fistula * Uncorrected congenital abnormality leading to urinary incontinence * Interstitial cystitis * Urinary urgency that results in leakage (as a predominant symptom) * Adult enuresis * Urodynamically proven d…